ALDX
|Aldeyra The
NASDAQ
USD 2.96
+0.28|+10.24%
Current Price
USD 2.96
Change
+USD 0.28 (10.24%)
P/E Ratio
Dividend Yield
Market Cap
132.97M
Volume
1.04M
Open
USD 2.70
Previous Close
USD 2.69
52-Week High
USD 7.20
52-Week Low
USD 1.14
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator th...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Todd C. Brady M.D., Ph.D.
Employees:8
Headquarters:Lexington, USA
Website:www.aldeyra.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions